New Search

If you are not happy with the results below please do another search

Generic filters

50 search results for:


BMS bets up to $1.9 billion on GentiBio’s Treg platform for IBD

Within the next eight years, more than 3.5 million people in the United States are expected to be diagnosed with inflammatory bowel disease. With those rising numbers in mind, Bristol Myers Squibb is doubling down on treating the condition with a nearly $2 billion partnership with GentiBio to develop Treg therapies for patients with IBD.


MIT makes possible breakthrough in enabling implantable insulin device

Research engineers from the Massachusetts Institute of Technology have found a way to prevent scar tissue from disabling implantable devices. If established as safe and effective in humans, this technology could prove transformative in treating many diseases, such as diabetes.